MedTrace Logo

MP1032 Treatment in Patients With Moderate to Severe COVID-19

NCT04932941 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 132

Last updated 2023-06-29

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy and safety of MP1032 with standard of care (SoC) verses placebo with SoC in hospitalized adults participants with moderate to severe coronavirus disease 2019 (COVID-19).

Conditions

Interventions

DRUG

MP1032

Hard gelatin capsules for oral administration.

DRUG

Placebo

Placebo capsules matched to MP1032 for oral administration.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-19
Primary Completion
2022-07-28
Completion
2022-09-05
FDA Drug
Yes

Countries

  • United States
  • Bulgaria
  • France
  • Hungary
  • Italy
  • Romania
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04932941 on ClinicalTrials.gov